EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma

Yasuo Mori, Jun Takizawa, Yuna Katsuoka, Naoki Takezako, Koji Nagafuji iD, Hiroshi Handa iD, Junya Kuroda iD, Kazutaka Sunami iD, Tomohiko Kamimura, Ryosuke Ogawa, Yoshikane Kikushige iD, Mine Harada und 3 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16158 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Science, 2024. Verfasst von Yasuo Mori und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ono Pharmaceutical, Bristol Myers Squibb K.K.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triplet regimen comprising proteasome inhibitors, immunomodulatory drugs, and dexamethasone (DEX) is a recommended induction/consolidation therapy for multiple myeloma (MM) patients eligible for transplant. In this Japanese phase II study conducted from 2017 to 2019, newly diagnosed MM patients aged 20–65 received four induction cycles with bortezomib (Bor), lenalidomide (Len), and DEX (VRD), followed by Bor and high‐dose melphalan with autologous stem cell rescue. Subsequently, they underwent four consolidation cycles with carfilzomib, Len, and DEX (KRD), followed by Len maintenance until disease progression. A total of 141 patients were analyzed. In an intent‐to‐treat population, the complete or better response post induction was 19.9%, rising to 39.7%, 58.9%, and 62.4% after transplant, consolidation, and 1‐year maintenance, respectively. With a median follow‐up of 38 months, the 3‐year progression‐free survival (PFS) rate was 83.5% and the 3‐year overall survival rate was 92.5%. Severe adverse events (≥grade 3) occurred in ~30% of patients; however, there was no treatment‐related mortality. These findings clearly showed the tolerability and effectiveness of this protocol. Nevertheless, patients with high‐risk cytogenetics showed a trend toward lower 3‐year PFS than those without (77.8% vs. 89.4%, p = 0.051), and ultra‐high‐risk cytogenetics (≥2 high‐risk cytogenetics) had an even worse prognosis, with 61.2% 3‐year PFS. To overcome this situation, a more potent treatment strategy incorporating novel agents such as the CD38‐antibody should be assessed in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideTransplantation, AutologousHematopoietic Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneBortezomibHumansMiddle AgedFemaleMaleAgedAdultConsolidation ChemotherapyMelphalanOligopeptidesInduction ChemotherapyProgression-Free SurvivalYoung AdultMaintenance Chemotherapy

Stichwörter der Autor:innen

autologous stem cell transplantationcombination therapyimmunomodulatory drugmultiple myelomaproteasome inhibitor

Substanzen

LenalidomideDexamethasoneBortezomibcarfilzomibMelphalanOligopeptides

Autor:innen und Institutionen

  • Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
  • Division of Hematology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
  • Department of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
  • Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Division of Hematology, Japan Association for Development of Community Medicine, Nerima Hikarigaoka Hospital, Tokyo, Japan.
  • Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

ORCID-Profile: Koji Nagafuji, Hiroshi Handa, Junya Kuroda, Kazutaka Sunami, Yoshikane Kikushige

Förderung

  • Ono Pharmaceutical
  • Bristol Myers Squibb K.K

Zitieren

APA

Mori, Y., Takizawa, J., Katsuoka, Y., Takezako, N., Nagafuji, K., Handa, H., Kuroda, J., Sunami, K., Kamimura, T., Ogawa, R., Kikushige, Y., Harada, M., Akashi, K., Miyamoto, T., & Japan Study Group for Cell Therapy and Transplantation (2024). Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer Science. https://doi.org/10.1111/cas.16158

Vancouver

Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, et al. Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma. Cancer Science. 2024. doi:10.1111/cas.16158

BibTeX
@article{Mori2024,
  author = {Mori, Yasuo and Takizawa, Jun and Katsuoka, Yuna and Takezako, Naoki and Nagafuji, Koji and Handa, Hiroshi and Kuroda, Junya and Sunami, Kazutaka and Kamimura, Tomohiko and Ogawa, Ryosuke and Kikushige, Yoshikane and Harada, Mine and Akashi, Koichi and Miyamoto, Toshihiro and Japan Study Group for Cell Therapy and Transplantation, Japan Study Group for Cell Therapy and Transplantation},
  title = {Autologous HSCT with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16158}
}
Kostenlos starten →